[1] Siegel, R., Ma, J., Zou, Z. and Jemal, A. (2014) Cancer Statistics, 2014. CA: A Cancer Journal for Clinicians, 64, 9-29.
http://dx.doi.org/10.3322/caac.21208
[2] Chaffer, C.L. and Weinberg, R.A. (2011) A Perspective on Cancer Cell Metastasis. Science, 331, 1559-1564.
http://dx.doi.org/10.1126/science.1203543
[3] Chambers, A.F., Groom, A.C. and MacDonald, I.C. (2002) Dissemination and Growth of Cancer Cells in Metastatic Sites. Nature Reviews Cancer, 2, 563-572.
http://dx.doi.org/10.1038/nrc865
[4] Williams, S.C. (2013) Circulating Tumor Cells. Proceedings of the National Academy of Sciences of the USA, 110, 4861.
http://dx.doi.org/10.1073/pnas.1304186110
[5] Plaks, V., Koopman, C.D. and Werb, Z. (2013) Cancer. Circulating Tumor Cells. Science, 341, 1186-1188.
http://dx.doi.org/10.1126/science.1235226
[6] Miller, M.C., Doyle, G.V. and Terstappen, L.W. (2010) Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer. Journal of Oncology, 2010, Article ID: 617421.
http://dx.doi.org/10.1155/2010/617421
[7] Smirnov, D.A., Zweitzig, D.R., Foulk, B.W., Miller, M.C., Doyle, G.V., Pienta, K.J., Meropol, N.J., Weiner, L.M., Cohen, S.J., Moreno, J.G., et al. (2005) Global Gene Expression Profiling of Circulating Tumor Cells. Cancer Research, 65, 4993-4997.
http://dx.doi.org/10.1158/0008-5472.CAN-04-4330
[8] Stott, S.L., Hsu, C.H., Tsukrov, D.I., Yu, M., Miyamoto, D.T., Waltman, B.A., Rothenberg, S.M., Shah, A.M., Smas, M.E., Korir, G.K., et al. (2010) Isolation of Circulating Tumor Cells Using a Microvortex-Generating Herringbone-Chip. Proceedings of the National Academy of Sciences of the USA, 107, 18392-18397.
http://dx.doi.org/10.1073/pnas.1012539107
[9] Gredelj-Simec, N., Jelic-Puskaric, B., Ostojic, A., Siftar, Z., Fiala, D., Kardum-Skelin, I., Vrhovac, R. and Jaksic, B. (2011) Diagnostic and Prognostic Significance of CD45 Cell Surface Antigen Expression in Hematologic Malignancies with Main Focus on Acute Leukemias. Acta Medica Croatica, 65, 45-52.
[10] Liu, L. and Shi, G.P. (2012) CD31: Beyond a Marker for Endothelial Cells. Cardiovascular Research, 94, 3-5.
http://dx.doi.org/10.1093/cvr/cvs108
[11] Sorenson, S.C., Asch, B.B., Connolly, J.L., Burstein, N.A. and Asch, H.L. (1987) Structural Distinctions among Human Breast Epithelial Cells Revealed by the Monclonal Antikeratin Antibodies AE1 and AE3. The Journal of Pathology, 153, 151-162.
http://dx.doi.org/10.1002/path.1711530208
[12] Gentile, A., Trusolino, L. and Comoglio, P.M. (2008) The Met Tyrosine Kinase Receptor in Development and Cancer. Cancer and Metastasis Reviews, 27, 85-94.
http://dx.doi.org/10.1007/s10555-007-9107-6
[13] Hollingsworth, M.A. and Swanson, B.J. (2004) Mucins in Cancer: Protection and Control of the Cell Surface. Nature Reviews Cancer, 4, 45-60.
http://dx.doi.org/10.1038/nrc1251
[14] Maria, T., Panagiotis, A., Marina, C., Eleni, K., Ioanna, V., Georgia, M. and Ioannis, P. (2014) How Prostate-Specific Membrane Antigen Level May Be Correlated with Stemness in Prostate Cancer Stem Cell-Like Cell Populations? Journal of Cancer Research and Therapeutics, 10, 133-141.
http://dx.doi.org/10.4103/0973-1482.131461
[15] Radford, K.J., Thorne, R.F. and Hersey, P. (1996) CD63 Associates with Transmembrane 4 Superfamily Members, CD9 and CD81, and with Beta 1 Integrins in Human Melanoma. Biochemical and Biophysical Research Communications, 222, 13-18.
http://dx.doi.org/10.1006/bbrc.1996.0690
[16] Linden, A. (2006) Measuring Diagnostic and Predictive Accuracy in Disease Management: An Introduction to Receiver Operating Characteristic (ROC) Analysis. Journal of Evaluation in Clinical Practice, 12, 132-139.
http://dx.doi.org/10.1111/j.1365-2753.2005.00598.x
[17] Mitchell, P.S., Parkin, R.K., Kroh, E.M., Fritz, B.R., Wyman, S.K., Pogosova-Agadjanyan, E.L., Peterson, A., Noteboom, J., O’Briant, K.C., Allen, A., et al. (2008) Circulating microRNAs as Stable Blood-Based Markers for Cancer Detection. Proceedings of the National Academy of Sciences of the United States of America, 105, 10513-10518.
http://dx.doi.org/10.1073/pnas.0804549105
[18] Toloudi, M., Apostolou, P., Chatziioannou, M. and Papasotiriou, I. (2011) Correlation between Cancer Stem Cells and Circulating Tumor Cells and Their Value. Case Reports in Oncology, 4, 44-54.
http://dx.doi.org/10.1159/000324403
[19] Pilo, A., Zucchelli, G.C., Cohen, R., Bizollon, C.A., Cappelli, G., Cianetti, A., Gion, M., Piffanelli, A. and Bombardieri, E. (1995) Comparison of Immunoassays for Tumor Markers CA 19-9, CA 15-3 and CA 125: Data from an International Quality Assessment Scheme. Tumori, 81, 117-124.
[20] Duffy, M.J. (2001) Clinical Uses of Tumor Markers: A Critical Review. Critical Reviews in Clinical Laboratory Sciences, 38, 225-262.
http://dx.doi.org/10.1080/20014091084218
[21] Tibbe, A.G., Miller, M.C. and Terstappen, L.W. (2007) Statistical Considerations for Enumeration of Circulating Tumor Cells. Cytometry Part A, 71, 154-162.
http://dx.doi.org/10.1002/cyto.a.20369
[22] Hermann, P.C., Huber, S.L., Herrler, T., Aicher, A., Ellwart, J.W., Guba, M., Bruns, C.J. and Heeschen, C. (2007) Distinct Populations of Cancer Stem Cells Determine Tumor Growth and Metastatic Activity in Human Pancreatic Cancer. Cell Stem Cell, 1, 313-323.
http://dx.doi.org/10.1016/j.stem.2007.06.002
[23] Kalluri, R. and Weinberg, R.A. (2009) The Basics of Epithelial-Mesenchymal Transition. Journal of Clinical Investigation, 119, 1420-1428.
http://dx.doi.org/10.1172/JCI39104
[24] Mani, S.A., Guo, W., Liao, M.J., Eaton, E.N., Ayyanan, A., Zhou, A.Y., Brooks, M., Reinhard, F., Zhang, C.C., Shipitsin, M., et al. (2008) The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells. Cell, 133, 704-715.
http://dx.doi.org/10.1016/j.cell.2008.03.027
[25] Riethdorf, S., Fritsche, H., Muller, V., Rau, T., Schindlbeck, C., Rack, B., Janni, W., Coith, C., Beck, K., Janicke, F., et al. (2007) Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the Cell Search System. Clinical Cancer Research, 13, 920-928.
http://dx.doi.org/10.1158/1078-0432.CCR-06-1695
[26] Marrinucci, D., Bethel, K., Lazar, D., Fisher, J., Huynh, E., Clark, P., Bruce, R., Nieva, J. and Kuhn, P. (2010) Cytomorphology of Circulating Colorectal Tumor Cells: A Small Case Series. Journal of Oncology, 2010, Article ID: 861341.
http://dx.doi.org/10.1155/2010/861341
[27] Meng, S., Tripathy, D., Frenkel, E.P., Shete, S., Naftalis, E.Z., Huth, J.F., Beitsch, P.D., Leitch, M., Hoover, S., Euhus, D., et al. (2004) Circulating Tumor Cells in Patients with Breast Cancer Dormancy. Clinical Cancer Research, 10, 8152-8162.
http://dx.doi.org/10.1158/1078-0432.CCR-04-1110
[28] Allard, W.J., Matera, J., Miller, M.C., Repollet, M., Connelly, M.C., Rao, C., Tibbe, A.G., Uhr, J.W. and Terstappen, L.W. (2004) Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but Not in Healthy Subjects or Patients with Nonmalignant Diseases. Clinical Cancer Research, 10, 6897-6904.
http://dx.doi.org/10.1158/1078-0432.CCR-04-0378
[29] Momburg, F., Moldenhauer, G., Hammerling, G.J. and Moller, P. (1987) Immunohistochemical Study of the Expression of a Mr 34,000 Human Epithelium-Specific Surface Glycoprotein in Normal and Malignant Tissues. Cancer Research, 47, 2883-2891.
[30] Pachmann, K., Camara, O., Kavallaris, A., Krauspe, S., Malarski, N., Gajda, M., Kroll, T., Jorke, C., Hammer, U., Altendorf-Hofmann, A., et al. (2008) Monitoring the Response of Circulating Epithelial Tumor Cells to Adjuvant Chemotherapy in Breast Cancer Allows Detection of Patients at Risk of Early Relapse. Journal of Clinical Oncology, 26, 1208-1215.
http://dx.doi.org/10.1200/JCO.2007.13.6523
[31] Cristofanilli, M. (2009) The Biological Information Obtainable from Circulating Tumor Cells. The Breast, 18, S38-S40.
http://dx.doi.org/10.1016/s0960-9776(09)70270-x
[32] Sterzynska, K., Kempisty, B., Zawierucha, P. and Zabel, M. (2012) Analysis of the Specificity and Selectivity of Anti-EpCAM Antibodies in Breast Cancer Cell Lines. Folia Histochemica et Cytobiologica, 50, 534-541.
http://dx.doi.org/10.5603/FHC.2012.0075
[33] Moncada, D.M., Kammanadiminti, S.J. and Chadee, K. (2003) Mucin and Toll-Like Receptors in Host Defense against Intestinal Parasites. Trends in Parasitology, 19, 305-311.
http://dx.doi.org/10.1016/S1471-4922(03)00122-3
[34] Wang, M.X., Earley Jr., J.J., Shields, J.A. and Donoso, L.A. (1992) An Ocular Melanoma-Associated Antigen. Molecular Characterization. Archives of Ophthalmology, 110, 399-404.
http://dx.doi.org/10.1001/archopht.1992.01080150097036
[35] Iida, J., Skubitz, A.P., McCarthy, J.B. and Skubitz, K.M. (2005) Protein Kinase Activity Is Associated with CD63 in Melanoma Cells. Journal of Translational Medicine, 3, 42.
http://dx.doi.org/10.1186/1479-5876-3-42
[36] O’Keefe, D.S., Bacich, D.J. and Heston, W.D. (2004) Comparative Analysis of Prostate-Specific Membrane Antigen (PSMA) versus a Prostate-Specific Membrane Antigen-Like Gene. Prostate, 58, 200-210.
http://dx.doi.org/10.1002/pros.10319
[37] Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., Sartore-Bianchi, A., Scala, E., Cassingena, A., Zecchin, D., et al. (2013) Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. Cancer Discovery, 3, 658-673.
http://dx.doi.org/10.1158/2159-8290.CD-12-0558